## Contents

*Dedication* ................................................................. v
*Preface* ........................................................................ vii
*Contributors* ............................................................... xiii

**Part I  Vaccines: Introduction**

1. Clinical Impact of Vaccine Development .......................... 3
   *Puja H. Nambiar, Alejandro Delgado Daza, and Lawrence L. Livornese Jr*

2. Future Challenges for Vaccinologists .............................. 41
   *Sunil Thomas, Rima Dilbarova, and Rino Rappuoli*

3. Principles of Vaccination ............................................. 57
   *Fred Zepp*

**Part II  Trends in Vaccinology**

4. Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines ............... 87
   *Marcin Michalik, Bardya Djahanshiri, Jack C. Leo, and Dirk Linke*

5. Systems Vaccinology: Applications, Trends, and Perspectives .......................................................... 107
   *Johannes Sollner*

6. Proteomic Monitoring of B Cell Immunity ....................... 131
   *Radwa Ewaisha and Karen S. Anderson*

**Part III  Vaccines for Human Viral Diseases**

   *Diego Fontana, Marina Etcheverrigaray, Ricardo Kratje, and Claudio Prieto*

8. Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine ................................................. 167
   *Anna Kabanova and Daniele Lilleri*

   *Shin Murakami, Kaori Terasaki, and Shinji Makino*

10. Application of Droplet Digital PCR to Validate Rift Valley Fever Vaccines .................................................. 207
    *Hoai J. Ly, Nandadeva Lokugamage, and Tetsuro Ikegami*

11. Methods to Evaluate Novel Hepatitis C Virus Vaccines .......... 221
    *Gustaf Ablén and Lars Frélín*

12. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus .................................................. 245
    *Gary Wong and Xiangguo Qiu*
13 Assessment of Functional Norovirus Antibody Responses by Blocking Assay in Mice .................................................. 259
Maria Malm, Kirsi Tamminen, and Vesna Blazevic

14 Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant .................................................. 269
Clifton McPherson, Richard Chubet, Kathy Holtz, Yoshikazu Honda-Okubo, Dale Barnard, Manon Cox, and Nikolai Petrovsky

15 Generation and Characterization of a Chimeric Tick-Borne Encephalitis Virus Attenuated Strain ChinTBEV .................................................. 285
Hong-Jiang Wang, Xiao-Feng Li, and Cheng-Feng Qin

16 Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses .................................................. 295
Michael A. Whitt, Thomas W. Geisbert, and Chad E. Mire

17 Reverse Genetics Approaches to Control Arenavirus .................................................. 313
Luis Martínez-Sobrido, Benson Yee Hin Cheng, and Juan Carlos de la Torre

PART IV VACCINES FOR HUMAN BACTERIAL DISEASES

18 DNA Vaccines: A Strategy for Developing Novel Multivalent TB Vaccines .......... 355
Jaemi S. Chu, Daniel O. Villarreal, and David B. Weiner

19 Overcoming Enterotoxigenic Escherichia coli Pathogen Diversity: Translational Molecular Approaches to Inform Vaccine Design .................................................. 363
James M. Fleckenstein and David A. Rasko

20 Design and Purification of Subunit Vaccines for Prevention of Clostridium difficile Infection .................................................. 385

21 The Design of a Clostridium difficile Carbohydrate-Based Vaccine .................................................. 397
Mario A. Monteiro

22 Murine Models of Bacteremia and Surgical Wound Infection for the Evaluation of Staphylococcus aureus Vaccine Candidates .................................................. 409
Linhui Wang and Jean C. Lee

23 Using MHC Molecules to Define a Chlamydia T Cell Vaccine .................................................. 419
Karuna P. Karunakaran, Hong Yu, Leonard J. Foster, and Robert C. Brunham

24 An Approach to Identify and Characterize a Subunit Candidate Shigella Vaccine Antigen .................................................. 433
Debasis Pore and Manoj K. Chakrabarti

25 Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine .................................................. 445
26 Anti-Lyme Subunit Vaccines: Design and Development of Peptide-Based Vaccine Candidates. ................................................. 471
Christina M. Small, Waithaka Mwangi, and Maria D. Esteve-Gassent

27 Assessment of Live Plague Vaccine Candidates. ................................. 487
Valentina A. Feodorova, Lidiya V. Sayapina, and Vladimir L. Motin

28 Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against *Yersinia pestis* .................. 499
Pan Tao, Marthandan Mahalingam, and Venigalla B. Rao

29 Development of Structure-Based Vaccines for Ehrlichiosis .................. 519
Sunil Thomas

PART V VACCINES FOR HUMAN FUNGAL DISEASES

30 Dendritic Cell-Based Vaccine Against Fungal Infection ....................... 537
Keigo Ueno, Makoto Urai, Kayo Obkouchi, Yoshitsugu Miyazaki, and Yuki Kinjo

31 Flow Cytometric Analysis of Protective T-Cell Response Against Pulmonary *Coccidioides* Infection ...................... 551
Chiung-Yu Hung, Karen L. Wozniak, and Garry T. Cole

PART VI VACCINES FOR HUMAN PARASITIC DISEASES

32 High-Density Peptide Arrays for Malaria Vaccine Development ............. 569
Felix F. Loeffler, Johannes Pfeil, and Kirsten Heiss

33 Development and Assessment of Transgenic Rodent Parasites for the Preclinical Evaluation of Malaria Vaccines .......... 583
Diego A. Espinosa, Andrea J. Radtke, and Fidel Zavala

34 DNA Integration in *Leishmania* Genome: An Application for Vaccine Development and Drug Screening ................... 603
Tabereb Taheri, Negar Seyed, and Sima Rafati

35 Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated *Leishmania* Parasite Vaccines ...... 623
Sreenivas Gannavaram, Parna Bhattacharya, Ranadhir Dey, Nevien Ismail, Kumar Avishek, Poonam Salotra, Angamuthu Selvapandiyan, Abhay Satoskar, and Hira L. Nakhasi

36 The Use of Microwave-Assisted Solid-Phase Peptide Synthesis and Click Chemistry for the Synthesis of Vaccine Candidates Against Hookworm Infection .......... 639
Abdullah A.H. Ahmad Fuaad, Mariusz Skwarczynski, and Istvan Toth

PART VII VACCINES FOR PRION DISEASES

37 Methods and Protocols for Developing Prion Vaccines ....................... 657
Kristen Marciniuk, Ryan Taschuk, and Scott Napper
PART VIII    VACCINES FOR SUBSTANCE ABUSE AND TOXINS

38 Ricin-Holotoxin-Based Vaccines: Induction of Potent
Ricin-Neutralizing Antibodies ................................. 683
Tamar Sabo, Chanoch Kronman, and Ohad Mazor

39 Synthesis of Hapten-Protein Conjugate Vaccines with Reproducible
Hapten Densities .................................................. 695
Oscar B. Torres, Carl R. Alving, and Gary R. Matyas

PART IX    VACCINES FOR ALLERGY

40 Production of Rice Seed-Based Allergy Vaccines .............. 713
Hidenori Takagi and Fumio Takaiwa

41 Allergy Vaccines Using a Mycobacterium-Secreted Antigen, Ag85B,
and an IL-4 Antagonist ........................................ 723
Yusuke Tsujimura and Yasuhiro Yasutomi

42 Development of House Dust Mite Vaccine ..................... 739
Qiuxiang Zhang and Chunqing Ai

PART X    DEVELOPMENT OF TUMOR VACCINES

43 Cancer Vaccines: A Brief Overview .......................... 755
Sunil Thomas and George C. Prendergast

44 Dendritic Cell Vaccines ...................................... 763
Rachel Lubong Sabado, Marcia Meseck, and Nina Bhardwaj

45 T-Cell Epitope Discovery for Therapeutic Cancer Vaccines .... 779
Sri Krishna and Karen S. Anderson

46 Peptide-Based Cancer Vaccine Strategies and Clinical Results .... 797
Erika Schneble, G. Travis Clifton, Diane F. Hale, and George E. Peoples

47 Preconditioning Vaccine Sites for mRNA-Transfected Dendritic
Cell Therapy and Antitumor Efficacy .......................... 819
Kristen A. Batich, Adam M. Swartz, and John H. Sampson

48 Development of Antibody-Based Vaccines Targeting the Tumor Vasculature .... 839
Xiaodong Zhuang and Roy Bicknell

PART XI    FORMULATION AND STABILITY OF VACCINES

49 Practical Approaches to Forced Degradation Studies of Vaccines .......... 853
Manvi Hasija, Sepideh Aboutorabian, Nausheen Rahman,
and Salvador F. Ausar

Index ................................................................. 867
Vaccine Design
Methods and Protocols: Volume 1: Vaccines for Human Diseases
Thomas, S. (Ed.)
2016, XIX, 873 p. 131 illus., 89 illus. in color., Hardcover
A product of Humana Press